Genflow Biosciences

Historical price data

Genflow Biosciences is a pre-clinical, publicly traded biotech focused on the ambitious mission of developing gene therapies to slow or halt the aging process. Its core strategy centers on delivering a protective 'centenarian variant' of the SIRT6 gene via AAV vectors, with lead programs targeting Werner syndrome in humans and aging in dogs. The company has established key scientific and clinical partnerships and is led by a team with extensive experience in gene therapy and biotech entrepreneurship, positioning itself at the forefront of the emerging longevity therapeutics sector.

AAV vector-based gene therapy platform designed to deliver a centenarian variant of the SIRT6 gene, a sirtuin protein implicated as a master regulator of DNA repair, metabolism, and inflammation in aging.

Genflow competes in the nascent longevity biotech sector against better-funded private companies (e.g., Altos Labs, Calico) and other gene therapy approaches. Its key differentiator is the specific centenarian variant of the SIRT6 gene, but it faces intense competition and scientific skepticism.